IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board

Related news

4basebio PLC - Cambridge, England-based life sciences company - Appoints mRNA biology and translation specialist Jeff Coller to its Strategic Advisory Board. Coller’s expertise will assist with the company’s efforts to reshape the scalable manufacturing of next-generation nucleic acid therapeutics.

Coller is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University and the Inaugural Director of the RNA Innovation Center. ‘Jeff’s groundbreaking discoveries in mRNA stability and translation are nothing short of transformative for our industry. His vision aligns perfectly with 4basebio‘s bold mission to dismantle the bottlenecks of traditional manufacturing. With Jeff on our Strategic Advisory Board, we are supercharging our ability to deliver the highest-performing synthetic DNA platforms to our partners - faster, purer, and built for the future of genetic medicine,’ says Chief Executive Amy Walker.

Current stock price: 540.00 pence

12-month change: down 45%

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Directors

Ways to help you invest your money

Our investment accounts

Put your money to work with our range of investment accounts. Choose from ISAs, pensions, and more.

Need some investment ideas?

Let us give you a hand choosing investments. From managed funds to favourite picks, we’re here to help.

Read our expert tips and insights

Our investment experts share their knowledge on how to keep your money working hard across the markets.